Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$8.69 USD

8.69
111,109

-0.04 (-0.46%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $8.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 16.67% and 9.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?

by Zacks Equity Research

INGN shows impressive momentum, driven by strong sales growth, an expanding product portfolio and significant advancements in portable oxygen technology.

Here's Why You Should Add Inogen Stock to Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.

Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?

by Zacks Equity Research

Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.

Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.

Inogen (INGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Inogen's (INGN) second-quarter 2024 results reflect significant improvement in the top and bottom lines, driven by strong international and domestic business-to-business sales.

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 55.56% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Soars 3.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OrthoPediatrics (KIDS) Soars 7.5%: Is Further Upside Left in the Stock?

by Zacks Equity Research

OrthoPediatrics (KIDS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.

Charles River (CRL) Advances in T-Cell Therapy With New Alliance

by Zacks Equity Research

Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.

Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ

by Zacks Equity Research

KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.

Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moumi Mondal headshot

Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?

by Moumi Mondal

Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.

Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.

Here's What Key Metrics Tell Us About Inogen (INGN) Q1 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Will These 5 Medical Device Stocks Beat This Earnings Season?

by Zacks Equity Research

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 50% and 9.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Up 26.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.

Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves

by Zacks Equity Research

Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Inogen (INGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Inogen (INGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of -75.38% and 2.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?